Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $4.60 Average PT from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received an average rating of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $4.60.

Separately, HC Wainwright cut their target price on Karyopharm Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, June 28th.

Insider Buying and Selling at Karyopharm Therapeutics

In other Karyopharm Therapeutics news, Director Deepika Pakianathan sold 360,744 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $1.00, for a total value of $360,744.00. Following the sale, the director now directly owns 11,209 shares of the company’s stock, valued at $11,209. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 1,275,473 shares of company stock valued at $1,234,542. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds have recently modified their holdings of the company. Bleakley Financial Group LLC purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth about $33,000. Simplicity Solutions LLC purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth about $33,000. Simplicity Wealth LLC purchased a new stake in shares of Karyopharm Therapeutics during the 1st quarter worth about $66,000. SG Americas Securities LLC boosted its stake in shares of Karyopharm Therapeutics by 295.0% during the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock worth $64,000 after acquiring an additional 54,839 shares in the last quarter. Finally, Monashee Investment Management LLC acquired a new position in shares of Karyopharm Therapeutics during the 4th quarter worth about $115,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI opened at $0.89 on Monday. The stock’s fifty day moving average price is $0.95 and its 200 day moving average price is $1.12. Karyopharm Therapeutics has a 1 year low of $0.62 and a 1 year high of $1.95. The company has a market cap of $110.91 million, a price-to-earnings ratio of -0.70 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01. The firm had revenue of $33.13 million during the quarter, compared to analyst estimates of $35.02 million. Research analysts expect that Karyopharm Therapeutics will post -1.16 earnings per share for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).